دورية أكاديمية
Metabolic instruction of the graft-versus-leukemia immunity.
| العنوان: | Metabolic instruction of the graft-versus-leukemia immunity. |
|---|---|
| المؤلفون: | Burk AC; German Cancer Consortium (DKTK), partner site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, Freiburg, Germany.; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Apostolova P; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.; Division of Hematology, University Hospital Basel, Basel, Switzerland. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Mar 04; Vol. 15, pp. 1347492. Date of Electronic Publication: 2024 Mar 04 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Graft vs Host Disease* , Leukemia, Myeloid, Acute*/therapy , Hematologic Neoplasms*, Humans ; T-Lymphocytes ; Graft vs Leukemia Effect ; Tumor Microenvironment |
| مستخلص: | Allogeneic hematopoietic cell transplantation (allo-HCT) is frequently performed to cure hematological malignancies, such as acute myeloid leukemia (AML), through the graft-versus-leukemia (GVL) effect. In this immunological process, donor immune cells eliminate residual cancer cells in the patient and exert tumor control through immunosurveillance. However, GVL failure and subsequent leukemia relapse are frequent and associated with a dismal prognosis. A better understanding of the mechanisms underlying AML immune evasion is essential for developing novel therapeutic strategies to boost the GVL effect. Cellular metabolism has emerged as an essential regulator of survival and cell fate for both cancer and immune cells. Leukemia and T cells utilize specific metabolic programs, including the orchestrated use of glucose, amino acids, and fatty acids, to support their growth and function. Besides regulating cell-intrinsic processes, metabolism shapes the extracellular environment and plays an important role in cell-cell communication. This review focuses on recent advances in the understanding of how metabolism might affect the anti-leukemia immune response. First, we provide a general overview of the mechanisms of immune escape after allo-HCT and an introduction to leukemia and T cell metabolism. Further, we discuss how leukemia and myeloid cell metabolism contribute to an altered microenvironment that impairs T cell function. Next, we review the literature linking metabolic processes in AML cells with their inhibitory checkpoint ligand expression. Finally, we focus on recent findings concerning the role of systemic metabolism in sustained GVL efficacy. While the majority of evidence in the field still stems from basic and preclinical studies, we discuss translational findings and propose further avenues for bridging the gap between bench and bedside. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Burk and Apostolova.) |
| References: | EBioMedicine. 2016 Dec;14:55-64. (PMID: 27916548) Clin Cancer Res. 2019 Jul 1;25(13):4079-4090. (PMID: 30940653) Blood. 1999 Apr 15;93(8):2738-47. (PMID: 10194454) Blood. 2007 May 1;109(9):3812-9. (PMID: 17255361) Carcinogenesis. 2017 Jan 3;38(3):271-280. (PMID: 28049629) Sci Adv. 2019 Jan 02;5(1):eaau7314. (PMID: 30613774) Science. 1994 Jul 22;265(5171):528-30. (PMID: 7518614) Blood. 2016 Oct 13;128(15):1944-1958. (PMID: 27540013) J Biol Chem. 2018 Feb 23;293(8):2877-2887. (PMID: 29326164) Nat Commun. 2021 Oct 26;12(1):6176. (PMID: 34702840) Oncoimmunology. 2016 Apr 28;5(7):e1178025. (PMID: 27622030) Trends Biochem Sci. 2014 Aug;39(8):347-54. (PMID: 25037503) Immunol Rev. 1998 Feb;161:95-109. (PMID: 9553767) Cancer Res. 1971 Aug;31(8):1159-65. (PMID: 5285976) Sci Adv. 2023 Apr 14;9(15):eadf8522. (PMID: 37058562) Nature. 2010 Feb 4;463(7281):676-80. (PMID: 20130650) PLoS One. 2013;8(3):e58397. (PMID: 23520507) Eur J Immunol. 1999 Apr;29(4):1275-85. (PMID: 10229095) Cell. 2014 Sep 11;158(6):1309-1323. (PMID: 25215489) Blood. 2013 Nov 14;122(20):3521-32. (PMID: 24014241) Lancet. 2009 May 2;373(9674):1550-61. (PMID: 19282026) Front Oncol. 2022 Jul 05;12:896426. (PMID: 35865470) Cell. 2016 Oct 20;167(3):829-842.e13. (PMID: 27745970) Clin Cancer Res. 2009 Oct 15;15(20):6348-57. (PMID: 19825957) Blood. 2007 Apr 1;109(7):2871-7. (PMID: 17164341) Front Pediatr. 2020 Jun 03;8:284. (PMID: 32582592) Oncol Lett. 2016 Jul;12(1):334-342. (PMID: 27347147) J Exp Med. 2007 Jun 11;204(6):1257-65. (PMID: 17502665) Blood. 2016 Jul 14;128(2):253-64. (PMID: 27257182) Nature. 2021 Mar;591(7851):645-651. (PMID: 33589820) Biol Res. 2002;35(1):9-26. (PMID: 12125211) Signal Transduct Target Ther. 2023 Sep 30;8(1):391. (PMID: 37777506) Transpl Int. 2005 Jan;18(1):95-100. (PMID: 15612990) Blood. 2020 Sep 24;136(13):1507-1519. (PMID: 32556243) Curr Opin Immunol. 2008 Oct;20(5):581-7. (PMID: 18675345) Nat Rev Immunol. 2013 May;13(5):349-61. (PMID: 23618831) Swiss Med Wkly. 2012 Aug 17;142:w13659. (PMID: 22903797) J Exp Med. 2010 Feb 15;207(2):339-44. (PMID: 20142433) Cancer Res. 2009 Mar 15;69(6):2677-84. (PMID: 19276380) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) Cancer Res. 2007 Jun 15;67(12):5949-56. (PMID: 17575165) Front Immunol. 2019 Jan 17;9:3179. (PMID: 30705680) Trends Immunol. 2012 May;33(5):231-7. (PMID: 22487321) J Clin Invest. 2016 Apr 1;126(4):1337-52. (PMID: 26950421) Clin Transl Immunology. 2019 Dec 24;8(12):e1098. (PMID: 31890207) Sci Adv. 2019 Jul 10;5(7):eaaw4304. (PMID: 31309149) Cell Chem Biol. 2023 Sep 21;30(9):1156-1168.e7. (PMID: 37689063) Nat Med. 2018 Dec;24(12):1859-1866. (PMID: 30420752) N Engl J Med. 2009 Jul 30;361(5):478-88. (PMID: 19641204) Proc Natl Acad Sci U S A. 2021 Jun 22;118(25):. (PMID: 34161266) Blood. 2017 Mar 23;129(12):1577-1585. (PMID: 28159741) Bone Marrow Transplant. 2010 Oct;45(10):1546-52. (PMID: 20190846) Nat Immunol. 2023 Mar;24(3):516-530. (PMID: 36732424) Blood. 2020 Jul 2;136(1):130-136. (PMID: 32430495) Nat Med. 2019 Apr;25(4):603-611. (PMID: 30911134) Immunity. 2012 Jan 27;36(1):68-78. (PMID: 22206904) Blood. 2013 Aug 1;122(5):749-58. (PMID: 23733335) Blood. 2014 Aug 14;124(7):1174-82. (PMID: 24939656) Blood Adv. 2016 Dec 14;1(3):193-204. (PMID: 29296935) Cancer Cell. 2010 Mar 16;17(3):225-34. (PMID: 20171147) Cancer Lett. 2015 Aug 1;364(1):1-7. (PMID: 25917076) Trends Mol Med. 2021 Apr;27(4):332-344. (PMID: 33121874) Cell Transplant. 2011;20(8):1221-30. (PMID: 21176405) Cell Host Microbe. 2023 Aug 9;31(8):1386-1403.e6. (PMID: 37463582) Mol Pharmacol. 1999 Mar;55(3):614-24. (PMID: 10051547) Science. 2002 Sep 13;297(5588):1867-70. (PMID: 12228717) Exp Mol Med. 2020 Jan;52(1):15-30. (PMID: 31980738) Front Immunol. 2018 Dec 21;9:3041. (PMID: 30619371) Eur Respir J. 2011 Jan;37(1):164-72. (PMID: 20562124) Biol Blood Marrow Transplant. 2015 Jun;21(6):1000-7. (PMID: 25459643) Leukemia. 2010 Mar;24(3):536-43. (PMID: 20072151) Biol Blood Marrow Transplant. 2015 Aug;21(8):1506-14. (PMID: 26001696) Br J Haematol. 2023 Mar;200(5):573-578. (PMID: 36413792) Blood Adv. 2023 Oct 10;7(19):5941-5953. (PMID: 37267439) Front Oncol. 2023 Jan 31;13:950732. (PMID: 36798819) Cancer Discov. 2023 Jul 7;13(7):1720-1747. (PMID: 37012202) Cancer Res. 2009 Mar 15;69(6):2260-8. (PMID: 19276390) Blood. 2018 Apr 12;131(15):1639-1653. (PMID: 29463564) Cancer Res. 1996 Feb 15;56(4):745-51. (PMID: 8631008) Leukemia. 2005 Jan;19(1):44-8. (PMID: 15496974) Br J Haematol. 2014 Jun;165(5):722-5. (PMID: 24666252) Biol Blood Marrow Transplant. 2015 Aug;21(8):1373-83. (PMID: 25977230) Front Immunol. 2018 Feb 09;9:176. (PMID: 29479351) JCI Insight. 2018 Mar 8;3(5):. (PMID: 29515031) Immunity. 2013 Apr 18;38(4):633-43. (PMID: 23601682) Blood. 1997 Aug 15;90(4):1600-10. (PMID: 9269779) J Immunol. 2013 Apr 1;190(7):3783-97. (PMID: 23440412) Cell. 2016 Sep 22;167(1):171-186.e15. (PMID: 27641501) J Immunol. 2015 Dec 1;195(11):5237-50. (PMID: 26491198) Cell Stem Cell. 2020 Nov 5;27(5):748-764.e4. (PMID: 32822582) Hematology Am Soc Hematol Educ Program. 2013;2013:335-41. (PMID: 24319201) Blood. 2010 Oct 28;116(17):3268-77. (PMID: 20628145) Leukemia. 2015 Feb;29(2):396-405. (PMID: 24897508) J Immunother. 2021 Oct 1;44(8):283-291. (PMID: 34133404) FEBS Lett. 1998 Jul 3;430(3):227-30. (PMID: 9688544) Trends Immunol. 2012 Apr;33(4):168-73. (PMID: 22342741) J Immunol. 1997 Mar 1;158(5):2065-75. (PMID: 9036950) Blood. 2017 Jan 12;129(2):199-208. (PMID: 27793879) Int J Mol Sci. 2023 Mar 22;24(6):. (PMID: 36983080) Leukemia. 2013 Apr;27(4):985-7. (PMID: 22982971) Nat Rev Immunol. 2005 Oct;5(10):793-806. (PMID: 16200082) Clin Cancer Res. 2018 Nov 1;24(21):5381-5391. (PMID: 30006485) Cancers (Basel). 2021 Jul 13;13(14):. (PMID: 34298712) Blood. 2015 Apr 9;125(15):2386-96. (PMID: 25710880) Nature. 2009 Dec 10;462(7274):739-44. (PMID: 19935646) Exp Hematol. 2017 Apr;48:1-11. (PMID: 28027963) J Immunol. 2009 Nov 1;183(9):5487-93. (PMID: 19843934) Leukemia. 2021 Oct;35(10):2813-2826. (PMID: 34193978) Leukemia. 2007 Feb;21(2):353-5. (PMID: 17170728) JAMA. 2017 Aug 8;318(6):557-566. (PMID: 28787506) Leuk Res. 2010 Oct;34(10):1383-9. (PMID: 20096930) Onco Targets Ther. 2022 Oct 18;15:1229-1243. (PMID: 36267609) Cell. 2017 Mar 9;168(6):960-976. (PMID: 28283069) Cancer Cell. 2018 Nov 12;34(5):724-740.e4. (PMID: 30423294) Blood. 2008 Dec 1;112(12):4371-83. (PMID: 19029455) Int J Cancer. 1980 Apr 15;25(4):463-6. (PMID: 6929272) Trends Endocrinol Metab. 2023 Jun;34(6):345-360. (PMID: 37061430) Cancer Res. 2012 Nov 1;72(21):5435-40. (PMID: 23090118) Blood. 2019 Mar 21;133(12):1290-1297. (PMID: 30578254) Clin Cancer Res. 2009 Oct 1;15(19):5956-61. (PMID: 19789308) iScience. 2020 Jan 24;23(1):100759. (PMID: 31887663) Best Pract Res Clin Haematol. 2019 Dec;32(4):101100. (PMID: 31779978) Blood. 2015 Mar 26;125(13):2120-30. (PMID: 25631767) Blood. 2004 Jun 1;103(11):4251-8. (PMID: 14976040) Cancer Immunol Immunother. 2011 Oct;60(10):1405-18. (PMID: 21638125) Lancet. 1968 Dec 28;2(7583):1366-9. (PMID: 4177932) Annu Rev Plant Biol. 2004;55:373-99. (PMID: 15377225) Biochem J. 2000 Aug 15;350 Pt 1:219-27. (PMID: 10926847) J Clin Oncol. 2007 Nov 1;25(31):4938-45. (PMID: 17909197) Cancer Cell. 2016 Nov 14;30(5):779-791. (PMID: 27746145) Cancer Chemother Pharmacol. 1987;20(4):344-8. (PMID: 3121203) Cancer Immunol Res. 2014 Mar;2(3):274-85. (PMID: 24778323) Blood. 2015 Jun 25;125(26):4060-8. (PMID: 25896651) J Biol Chem. 1986 Mar 15;261(8):3648-53. (PMID: 2419335) Cancer Res. 2010 Jan 1;70(1):68-77. (PMID: 20028852) Blood. 2012 May 10;119(19):4554-64. (PMID: 22262774) J Immunother Cancer. 2016 Aug 16;4:49. (PMID: 27532024) JCI Insight. 2018 Sep 20;3(18):. (PMID: 30232291) J Chemother. 2020 Feb;32(1):30-40. (PMID: 31775585) Front Oncol. 2021 Dec 16;11:812207. (PMID: 34976845) J Allergy Clin Immunol. 2021 Jan;147(1):335-348.e11. (PMID: 32407834) Biol Blood Marrow Transplant. 2019 Apr;25(4):e128-e140. (PMID: 30658222) Br J Cancer. 1997;76(3):365-70. (PMID: 9252204) Cell Chem Biol. 2018 Jun 21;25(6):705-717.e11. (PMID: 29628435) Blood. 2017 Oct 5;130(14):1649-1660. (PMID: 28733324) Front Immunol. 2021 Mar 31;12:652687. (PMID: 33868291) Blood. 2019 Jan 3;133(1):7-17. (PMID: 30361262) Cancer Immunol Immunother. 2014 Jul;63(7):721-35. (PMID: 24711084) Bone Marrow Transplant. 2012 May;47(5):651-6. (PMID: 21765480) Nat Commun. 2022 Nov 8;13(1):6740. (PMID: 36347860) Cells. 2019 Jul 31;8(8):. (PMID: 31370337) Front Endocrinol (Lausanne). 2020 Jun 09;11:365. (PMID: 32582032) Blood. 2014 Sep 4;124(10):1645-54. (PMID: 25006128) J Immunol. 2011 Mar 15;186(6):3299-303. (PMID: 21317389) Haematologica. 2024 Jan 18;:. (PMID: 38235501) Trends Immunol. 2015 Apr;36(4):257-64. (PMID: 25773310) Biol Blood Marrow Transplant. 2009 May;15(5):580-8. (PMID: 19361750) Nat Cancer. 2020 Dec;1(12):1176-1187. (PMID: 33884374) Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14336-41. (PMID: 23940348) Sci Transl Med. 2018 Feb 21;10(429):. (PMID: 29467301) Annu Rev Immunol. 2018 Apr 26;36:461-488. (PMID: 29677474) Stem Cells. 1997;15(4):248-58. (PMID: 9253108) Trends Immunol. 2003 May;24(5):242-8. (PMID: 12738417) Adv Exp Med Biol. 1999;467:517-24. (PMID: 10721095) Sci Transl Med. 2020 Oct 28;12(567):. (PMID: 33115954) Cell Death Differ. 2021 Aug;28(8):2465-2481. (PMID: 33742137) J Exp Med. 1999 May 3;189(9):1363-72. (PMID: 10224276) Nat Med. 2018 Aug;24(8):1192-1203. (PMID: 29988124) Stem Cell Res. 2011 Jul;7(1):66-74. (PMID: 21546330) Best Pract Res Clin Haematol. 2007 Mar;20(1):13-8. (PMID: 17336250) PLoS One. 2016 Sep 06;11(9):e0162217. (PMID: 27598335) Immunity. 2014 Jul 17;41(1):75-88. (PMID: 25001241) J Clin Oncol. 2002 Jan 15;20(2):405-12. (PMID: 11786567) Exp Hematol. 2014 Jul;42(7):574-80. (PMID: 24607957) Cell Stem Cell. 2021 Oct 7;28(10):1851-1867.e8. (PMID: 34293334) Circ Res. 2004 Oct 15;95(8):814-21. (PMID: 15358667) J Biol Chem. 2018 May 18;293(20):7490-7498. (PMID: 29339555) Front Oncol. 2019 Nov 19;9:1217. (PMID: 31803612) Front Oncol. 2022 Feb 10;12:807266. (PMID: 35223487) Front Immunol. 2020 Feb 25;11:147. (PMID: 32158444) Blood Adv. 2024 Jan 9;8(1):56-69. (PMID: 37906522) Blood. 2023 Apr 6;141(14):1718-1723. (PMID: 36563336) Cancer Discov. 2017 Apr;7(4):391-399. (PMID: 28255083) J Clin Med. 2015 Mar 19;4(3):488-503. (PMID: 26239251) Blood. 2009 Mar 12;113(11):2394-401. (PMID: 19023117) Front Immunol. 2017 Jun 07;8:496. (PMID: 28638379) Oncotarget. 2014 Apr 30;5(8):2052-64. (PMID: 24903009) J Immunol. 2006 Jul 15;177(2):852-62. (PMID: 16818739) J Proteome Res. 2013 Oct 4;12(10):4393-401. (PMID: 23998518) Sci Transl Med. 2019 Aug 7;11(504):. (PMID: 31391321) Science. 2023 Sep 22;381(6664):1316-1323. (PMID: 37733872) Ann Clin Lab Sci. 2008 Spring;38(2):120-5. (PMID: 18469356) Front Oncol. 2022 Jun 08;12:846149. (PMID: 35756656) Blood. 2023 Mar 30;141(13):1626-1639. (PMID: 36564029) Annu Rev Immunol. 2013;31:259-83. (PMID: 23298210) Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204) J Exp Med. 2015 Aug 24;212(9):1345-60. (PMID: 26261266) Blood. 2019 Jul 25;134(4):389-394. (PMID: 31101624) Front Oncol. 2020 Feb 18;10:155. (PMID: 32133293) Leukemia. 2017 Oct;31(10):2143-2150. (PMID: 28194038) Science. 2022 Sep 30;377(6614):1519-1529. (PMID: 36173860) Purinergic Signal. 2006 Jun;2(2):351-60. (PMID: 18404475) Blood. 2014 Jul 31;124(5):750-60. (PMID: 24850760) Leuk Lymphoma. 1997 Dec;28(1-2):33-42. (PMID: 9498701) Immunol Today. 1999 Oct;20(10):469-73. (PMID: 10500295) Ann Bot. 2003 Jan;91 Spec No:179-94. (PMID: 12509339) Cell Metab. 2017 Jul 5;26(1):94-109. (PMID: 28683298) J Cell Physiol. 2010 Jan;222(1):17-22. (PMID: 19725055) Proc Natl Acad Sci U S A. 2023 Jun 13;120(24):e2305245120. (PMID: 37276392) Immunity. 2021 Jan 12;54(1):116-131.e10. (PMID: 33271120) Thromb Haemost. 1999 Nov;82(5):1538-44. (PMID: 10595651) Blood. 2017 Mar 9;129(10):1320-1332. (PMID: 28049638) Apoptosis. 2015 Aug;20(8):1099-108. (PMID: 25998464) Trends Immunol. 2005 Jun;26(6):299-304. (PMID: 15922945) Nat Immunol. 2016 May;17(5):505-513. (PMID: 26998764) Leukemia. 2022 Jan;36(1):1-12. (PMID: 34561557) Sci Transl Med. 2011 Jan 26;3(67):67ra8. (PMID: 21270339) Int J Cancer. 2019 Oct 15;145(8):2201-2208. (PMID: 30485425) N Engl J Med. 2018 Dec 13;379(24):2330-2341. (PMID: 30380364) Cancer Cell. 2018 Oct 8;34(4):659-673.e6. (PMID: 30270124) Science. 1956 Feb 24;123(3191):309-14. (PMID: 13298683) Science. 2022 Oct 28;378(6618):eabj3510. (PMID: 36302005) N Engl J Med. 1957 Sep 12;257(11):491-6. (PMID: 13464965) |
| فهرسة مساهمة: | Keywords: T cells; acute myeloid leukemia; allogeneic hematopoietic cell transplantation; anti-tumor immunity; graft-versus-leukemia effect; metabolism |
| تواريخ الأحداث: | Date Created: 20240319 Date Completed: 20240320 Latest Revision: 20240411 |
| رمز التحديث: | 20240411 |
| مُعرف محوري في PubMed: | PMC10944922 |
| DOI: | 10.3389/fimmu.2024.1347492 |
| PMID: | 38500877 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1347492 |